Cutia Therapeutics Future Growth
Future criteria checks 2/6
Cutia Therapeutics is forecast to grow earnings and revenue by 89.5% and 39.2% per annum respectively. EPS is expected to grow by 102.9% per annum. Return on equity is forecast to be -35.7% in 3 years.
Key information
89.5%
Earnings growth rate
102.9%
EPS growth rate
Biotechs earnings growth | 35.6% |
Revenue growth rate | 39.2% |
Future return on equity | -35.7% |
Analyst coverage | Low |
Last updated | 02 Apr 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 940 | -156 | -294 | N/A | 2 |
12/31/2025 | 487 | -385 | -295 | N/A | 4 |
12/31/2024 | 282 | -486 | -529 | N/A | 3 |
12/31/2023 | 138 | -1,964 | N/A | N/A | N/A |
6/30/2023 | 45 | -1,945 | -416 | -304 | N/A |
3/31/2023 | 28 | -1,250 | -394 | -270 | N/A |
12/31/2022 | 11 | -556 | -372 | -236 | N/A |
12/31/2021 | 2 | -320 | -186 | -160 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2487 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2487 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2487 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2487's revenue (39.2% per year) is forecast to grow faster than the Hong Kong market (8% per year).
High Growth Revenue: 2487's revenue (39.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2487 is forecast to be unprofitable in 3 years.